Immuneering Corp
NASDAQ:IMRX

  • LAST PRICE
    2.1100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.1100/ 3
  • Ask / Lots
    2.1800/ 9
  • Open / Previous Close
    --- / 2.1100
  • Day Range
    ---
  • 52 Week Range
    1.0000
    8.8900
  • Volume
    9,899

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 20, 2024

  • Nov 14, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: IMRX

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: IMRX

      laurence@newstreetir.com
      IMMUNEERING CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Three Months Ended September Nine Months Ended September 30, 30, ----------------------------- ------------------------------ 2024 2023 2024 2023 ----------- ----------- ----------- ----------- Operating expenses Research and development $ 11,252,850 $ 10,050,198 $ 33,107,222 $ 29,713,835 General and administrative 4,013,581 3,868,823 12,384,074 12,375,114 Amortization of intangible asset 7,317 7,317 21,950 21,950 ----------- ----------- ----------- ----------- Total operating expenses 15,273,748 13,926,338 45,513,246 42,110,899 ----------- ----------- ----------- ----------- Loss from operations (15,273,748) (13,926,338) (45,513,246) (42,110,899) Other income (expense) Interest income 547,072 855,532 2,178,060 2,852,852 Other income, net 129,310 475,595 350,063 869,917 Net loss $(14,597,366) $(12,595,211) $(42,985,123) $(38,388,130) =========== =========== =========== =========== Net loss per share attributable to common stockholders, basic and diluted $ (0.49) $ (0.43) $ (1.45) $ (1.36) =========== =========== =========== =========== Weighted-average common shares outstanding, basic and diluted 29,841,883 29,266,309 29,622,670 28,129,005 =========== =========== =========== =========== Other comprehensive income (loss): Unrealized gains from marketable securities 7,845 7,825 8,624 35,727 Comprehensive Loss $(14,589,521) -$(12,587,386) $(42,976,499) $(38,352,403) =========== =========== =========== =========== IMMUNEERING CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2024 December 31, 2023 -------------------- --------------------- Assets Current assets: Cash and cash equivalents $ 45,205,577 $ 59,405,817 Marketable securities 5,452,155 26,259,868 Prepaids and other current assets 4,601,769 3,417,984 --------------- -------------- Total current assets 55,259,501 89,083,669 Property and equipment, net 1,205,095 1,400,582 Goodwill 6,690,431 6,690,431 Intangible asset, net 357,730 379,680 Right-of-use assets, net 3,748,565 3,995,730 Other assets 1,295,782 1,034,446 Total assets $ 68,557,104 $ 102,584,538 =============== ============== Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,942,782 $ 2,111,666 Accrued expenses 4,592,825 5,173,960 Other liabilities 59,657 259,770 Lease liabilities 324,702 300,107 --------------- -------------- Total current liabilities 6,919,966 7,845,503 Long-term liabilities: Lease liabilities, net of current portion 3,916,324 4,162,852 Total liabilities 10,836,290 12,008,355 --------------- -------------- Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; 0 shares issued or outstanding at September 30, 2024 and December 31, 2023 - - Class A common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 31,050,448 and 29,271,629 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 31,050 29,272 Class B common stock, $0.001 par value, 20,000,000 shares authorized at September 30, 2024 and December 31, 2023; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023 - - Additional paid-in capital 263,925,619 253,806,267 Accumulated other comprehensive loss 7,845 (778) Accumulated deficit (206,243,700) (163,258,578) Total stockholders' equity 57,720,814 90,576,183 --------------- -------------- Total liabilities and stockholders' equity $ 68,557,104 $ 102,584,538 =============== ==============

Peers Headlines